Acquisition Announced
Eli Lilly and Company acquisition of Ajax Therapeutics
US$2.3bn consideration
Announced 27 Apr 2026
Advisers
Ajax Therapeutics
Target
- Legal adviser
- Cooley
Team: Kevin Cooper, Sangitha Palaniappa, Brandon Fenn, Kenneth Krisko, Stephanie Palmer, Megan Browdie, Sarah Buchik, Navya Dasari, Alex Fullman, Jenny Ge, Stephanie Gentile, Tony Guan, Josh Holtzman, Nicollette Kirby, Natasha Leskovsek, Sarah Miller, Phil Mitchell, Ryan Montgomery, Morgan Perna, Joe Perry, Breanna Qin, Carly Robinson, Patrick Sharma, Daniel Tsai, Karen Tsai, Ryan Vann, Bo Yaghmaie
- Target
- Ajax Therapeutics
- Acquirer
- Eli Lilly and Company
- Target based in
- United States (unverified)
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development, Oncology
In the league tables
Similar deals
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- Gilead Sciences acquisition of Tubulis Apr 2026 · US$3.1bn · Biotech
- Amgen acquisition of Dark Blue Therapeutics Jan 2026 · US$840m · Biotech
- Merck & Co. acquisition of Terns Pharmaceuticals Mar 2026 · US$6.7bn · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
Sources
- 27 Apr 2026 Ajax Therapeutics Acquired By Eli Lilly for $2.3 Billion cooley.com
- 27 Apr 2026 Press release (PR Newswire), Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera prnewswire.com
